EHHADH
Peroxisomal bifunctional enzyme
Also known as: ECHD, ECHP_HUMAN
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- Q08426
- Gene
- EHHADH
- Ensembl
- ENSG00000113790
- Chromosome
- 3
- Canonical length
- 723 aa
- Protein class
- Disease related genes, Enzymes, Human disease related genes, Metabolic proteins, Plasma proteins, Potential drug targets, Predicted intracellular proteins
OverviewNCBI Gene
The protein encoded by this gene is a bifunctional enzyme and is one of the four enzymes of the peroxisomal beta-oxidation pathway. The N-terminal region of the encoded protein contains enoyl-CoA hydratase activity while the C-terminal region contains 3-hydroxyacyl-CoA dehydrogenase activity. Defects in this gene are a cause of peroxisomal disorders such as Zellweger syndrome. Two transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Oct 2009]
Canonical amino-acid sequenceUniProt
723 residues, UniProt reviewed canonical sequence.
>Q08426|EHHADH
1 MAEYTRLHNA LALIRLRNPP VNAISTTLLR DIKEGLQKAV IDHTIKAIVI CGAEGKFSAG
61 ADIRGFSAPR TFGLTLGHVV DEIQRNEKPV VAAIQGMAFG GGLELALGCH YRIAHAEAQV
121 GLPEVTLGLL PGARGTQLLP RLTGVPAALD LITSGRRILA DEALKLGILD KVVNSDPVEE
181 AIRFAQRVSD QPLESRRLCN KPIQSLPNMD SIFSEALLKM RRQHPGCLAQ EACVRAVQAA
241 VQYPYEVGIK KEEELFLYLL QSGQARALQY AFFAERKANK WSTPSGASWK TASARPVSSV
301 GVVGLGTMGR GIVISFARAR IPVIAVDSDK NQLATANKMI TSVLEKEASK MQQSGHPWSG
361 PKPRLTSSVK ELGGVDLVIE AVFEEMSLKK QVFAELSAVC KPEAFLCTNT SALDVDEIAS
421 STDRPHLVIG THFFSPAHVM KLLEVIPSQY SSPTTIATVM NLSKKIKKIG VVVGNCFGFV
481 GNRMLNPYYN QAYFLLEEGS KPEEVDQVLE EFGFKMGPFR VSDLAGLDVG WKSRKGQGLT
541 GPTLLPGTPA RKRGNRRYCP IPDVLCELGR FGQKTGKGWY QYDKPLGRIH KPDPWLSKFL
601 SRYRKTHHIE PRTISQDEIL ERCLYSLINE AFRILGEGIA ASPEHIDVVY LHGYGWPRHK
661 GGPMFYASTV GLPTVLEKLQ KYYRQNPDIP QLEPSDYLKK LASQGNPPLK EWQSLAGSPS
721 SKLLocalizationUniProt · AlphaFold · HPA
Whether an antibody against EHHADH can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Intracellular
- Secreted
- No
- Transmembrane segments
- 0
- Mean surface accessibility (rSASA)
- 0.23
- Highest tissue expression
- 322 nTPM
Expression across tissuesHPA
Tissue
- liver: 322 nTPM
- kidney: 135 nTPM
- duodenum: 20 nTPM
- colon: 13 nTPM
- choroid plexus: 12 nTPM
- small intestine: 12 nTPM
Single-cell type
- hepatocytes: 402 nCPM
- proximal tubule cells: 272 nCPM
- retinal pigment epithelial cells: 85 nCPM
- adipocytes: 78 nCPM
- renal collecting duct principal cells: 48 nCPM
- choroid plexus epithelial cells: 48 nCPM
Immune cell
- myeloid DC: 2.4 nTPM
- NK-cell: 1.2 nTPM
- naive CD8 T-cell: 1 nTPM
- plasmacytoid DC: 1 nTPM
- classical monocyte: 0.9 nTPM
- memory CD8 T-cell: 0.9 nTPM
Brain region
- choroid plexus: 20 nTPM
- midbrain: 9.9 nTPM
- cerebellum: 9.5 nTPM
- hypothalamus: 7.9 nTPM
- medulla oblongata: 7.9 nTPM
- pons: 7.8 nTPM
DiseaseUniProt · ClinVar · IEDB · PubMed
Four sources answering four different questions about EHHADH.
Disease | AllUniProt
Conditions EHHADH is implicated in, by any mechanism.
- Fanconi renotubular syndrome 3 (FRTS3) MIM:615605
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 0.97
- gnomAD pLI
- 0
- gnomAD missense Z
- -0.03
- DepMap mean gene effect
- -0.06
- DepMap dependency class
- none
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 10% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
- alpha-linolenic acid metabolic process
- fatty acid beta-oxidation
- fatty acid beta-oxidation using acyl-CoA oxidase
- fatty acid derivative biosynthetic process
- long-chain fatty acid biosynthetic process
- unsaturated fatty acid biosynthetic process
Molecular functions
- (3S)-3-hydroxyacyl-CoA dehydrogenase (NAD+) activity
- 3-hydroxyacyl-CoA dehydratase activity
- delta(3)-delta(2)-enoyl-CoA isomerase activity
- enoyl-CoA hydratase activity
- enzyme binding
- intramolecular oxidoreductase activity, transposing C=C bonds
- long-chain (3S)-3-hydroxyacyl-CoA dehydrogenase (NAD+) activity
- NAD+ binding
Cellular components
Protein domainsUniProt · Pfam · InterPro
- Enoyl-CoA hydratase/isomerase-like domain
- 3-hydroxyacyl-CoA dehydrogenase, C-terminal
- 3-hydroxyacyl-CoA dehydrogenase, NAD binding
- 3-hydroxyacyl-CoA dehydrogenase, conserved site
- 6-phosphogluconate dehydrogenase-like, C-terminal domain superfamily
- Enoyl-CoA hydratase/isomerase, conserved site
- ClpP/crotonase-like domain superfamily
- NAD(P)-binding domain superfamily
- Enoyl-CoA hydratase/isomerase
- 3-hydroxyacyl-CoA dehydrogenase, C-terminal domain
- 3-hydroxyacyl-CoA dehydrogenase, NAD binding domain
KeywordsUniProt
InteractionsUniProt · HPA
Protein binding partners of EHHADH in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads EHHADH as an antibody target. Whether an autoantibody or antibody against EHHADH could matter depends on whether native EHHADH is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
EHHADH is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.
Annotation status
The present source text does not explicitly label EHHADH as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...